ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens

Author's Avatar
Feb 10, 2023

Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens produced questionable results due to a high disease burden among tested chickens.